Neurological manifestations associated with SARS-CoV-2 infection: an updated review.
Author:
Cevallos-Macías Diana1ORCID, Vizcaíno Salazar Gilberto2ORCID, Siteneski Aline2ORCID
Affiliation:
1. Facultad de Ciencias de la Salud, Carrera de Medicina, Universidad Técnica de Manabí, Portoviejo, Ecuador. 2. Facultad de Ciencias de la Salud, Carrera de Medicina, Universidad Técnica de Manabí, Portoviejo, Ecuador. Instituto de Investigación y Facultad de Ciencias de la Salud, Universidad Técnica de Manabí, Portoviejo, Ecuador.
Abstract
SARS-CoV-2 is a single-stranded RNA virus that belongs to the group of seven coronaviruses that affect humans, and its infection causes the COVID-19 disease. The association between the COVID-19 condition and risk factors of neurological manifestations is unclear to date. This review aims to update the main neurological manifestations associated with SARS-CoV-2 disease. First, we present the hypothesis of the neuroinvasion mechanisms of SARS-CoV-2. Then, we discuss the possible symptoms related to patients with COVID-19 infection in the central and peripheral nervous systems, followed by the perspectives of diagnosis and treatment of possible neurological manifesta-tions. The hypothesis of the neuroinvasion mechanism includes direct routes, as the virus crosses the blood-brain barrier or the ACE2 receptor pathway role, and indirect pathways, such as malfunctions of the immune system and vascular system dysregulation. Various studies report COVID-19 consequences, such as neuroanatomic alterations and cognitive impairment, besides peripheral condi-tions, such as anosmia, ageusia, and Guillain Barré Syndrome. However, the het-erogeneity of the studies about neurologic damage in patients after COVID-19 infection precludes any generalization of current findings. Finally, new studies are necessary to understand the adequate diagnosis, therapeutic method of early treatment, and risk group of patients for neurological manifestations of COVID-19 post-infection.
Publisher
Universidad del Zulia
Reference87 articles.
1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui D, Du B, Li L, Zeng G, Yuen K, Chen R, Tang C, Wang T, Chen P, Xiang J, Li S, Wang J, Liang Z, Peng Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo J, Ye C, Zhu S, Zhong N. Clinical characteris-tics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-1720. https://doi.org/10.1056/NEJMoa2002032. 2. Wan D, Du T, Hong W, Chen L, Que H, Lu S, Peng X. Neurological complications and infec-tion mechanism of SARS-CoV-2. Signal Trans-duct Target Ther 2021; 6(1): 1-11. https://doi.org/10.1038/s41392-021-00818-7. 3. Pei S, Yamana TK, Kandula S, Galanti M, Shaman J. Burden and characteristics of COVID-19 in the United States during 2020. Nature 2021; 598(7880): 338–341. https://doi.org/10.1038/s41586-021-03914-4. 4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao G, Tan W. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727–733. https://doi.org/10.1056/NEJMoa2001017. 5. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger A, Pipavath S, Wurfel M, Evans L, Kri-tek P, West T, Luks A, Gerbino A, Dale C, Goldman J, O’Mahony S, Mikacenic C. Covid-19 in critically Ill patients in the Seattle Region — case series. N Engl J Med 2020; 382(21): 2012–2022. https://doi.org/10.1056/NEJMoa2004500.
|
|